Insilico Medicine Secures $110 Million Series E Financing to Advance AI-Driven Drug Discovery Innovation [Yahoo! Finance]
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Royal Bank of Canada from $38.00 to $40.00. They now have an "outperform" rating on the stock.
Qiming-Backed AI Drug Discovery Startup Insilico Medicine Hits Unicorn Status With $110 Million Funding Round [Forbes]
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March